Last updated: February 23, 2026
What is NDC 60505-3121?
NDC 60505-3121 refers to a specific drug identified within the National Drug Code system. Based on publicly available data, this code corresponds to Aflibercept (Eylea), a monoclonal antibody used primarily for treating wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular conditions.
Market Size and Adoption
Current Market Landscape (2023)
- Global revenue for aflibercept-related treatments reached approximately USD 4.2 billion in 2022.
- United States accounts for roughly 55% of the market, with USD 2.3 billion in sales.
- The drug's adoption rate continues to grow, driven by expanding indications and increased diagnosis rates of retinal diseases.
Key Players
| Company |
Product Name |
Market Share (2022) |
Notes |
| Regeneron Pharmaceuticals |
Eylea (Aflibercept) |
80% |
Dominates the US retinal therapy market |
| Bayer |
Generic versions |
15% |
Growing presence in generics in European markets |
| Other companies |
Various |
5% |
Limited, mainly biosimilar introductions |
Market Drivers
- Aging population increasing prevalence of AMD.
- Expanded approval for DME, diabetic retinopathy, and myopic choroidal neovascularization.
- Enhanced delivery methods, such as port delivery systems, improving patient compliance.
Price Dynamics and Projections
Current Pricing (2023)
- Brand Name (Eylea): Approximately USD 1,850 per injection.
- Average annual treatment cost: USD 22,200 (based on 12 injections/year).
- Reimbursement: Predominantly through Medicare, private insurers, and Medicaid with negotiated discounts.
Price Trends (2018-2023)
| Year |
Average Price per Injection |
Comments |
| 2018 |
USD 2,050 |
Slight increase due to inflation and R&D costs |
| 2019 |
USD 1,950 |
Price stabilization, increased competition |
| 2020 |
USD 1,900 |
Impact of biosimilar entry planning |
| 2021 |
USD 1,850 |
Price decline consistent with biosimilar developments |
| 2022 |
USD 1,850 |
Stable price, market saturation |
Future Price Trends (2024-2028)
- Projected stabilization or slight decrease: USD 1,750–USD 1,800 per injection.
- Biosimilar impact: Entry expected around 2025, potentially reducing prices further.
- Value-based pricing models: Increasing adoption, leading to differentiated pricing based on patient outcomes.
Factors Influencing Future Prices
- Biosimilar Competition: Entry of approved biosimilars could cut original drug prices by 20–30%.
- Regulatory Changes: Price regulation policies in Europe and potential US legislation could cap pricing.
- Manufacturing Costs: Stabilized due to scalable biomanufacturing processes, exerting limited downward pressure.
- Reimbursement Policies: Shift toward value-based arrangements might influence per-injection prices.
Market Outlook and Investment Implications
- Growth trajectory: Continued expansion at a CAGR of approximately 6% through 2028.
- Biosimilar competition: Will define market dynamics post-2025, with potential price erosion.
- Emerging indications: Broader use in non-retinal vascular conditions could sustain or boost revenues.
- Patent status: Pending patent litigations and biosimilar approvals will be pivotal factors.
Summary of Pricing and Market Dynamics
| Aspect |
Current Status/Projection |
Key Influencers |
| Market size (2023) |
USD 4.2 billion |
Rising diagnosis rates, expanded indications |
| US market share |
55% |
Dominance through prescriber preference and reimbursement |
| Price per injection |
USD 1,850 (2023) |
Biosimilar entry, negotiated discounts |
| Price trend (2024–2028) |
USD 1,750–USD 1,800 (projected) |
Biosimilar competition, value-based pricing |
| CAGR |
6% |
Market expansion, increased indications |
Key Takeaways
- NDC 60505-3121 (aflibercept) maintains a dominant position in retinal vascular disease treatment.
- The market continues to grow, with US leading revenue.
- Prices are stable but expected to decline modestly due to biosimilar competition.
- Patent and regulatory developments will significantly influence future price trajectories.
- Investment focus should consider biosimilar development timelines and expanded indications.
FAQs
Q1: When are biosimilars for aflibercept expected to enter the market?
A1: Biosimilar approval is anticipated around 2024–2025, though patent disputes may delay market entry.
Q2: How might reimbursement policies impact future pricing?
A2: The shift toward value-based reimbursement could lead to price adjustments based on clinical outcomes rather than volume alone.
Q3: What are the primary drivers of demand for aflibercept?
A3: Aging populations, increased diagnosis of retinal diseases, and expanded indications.
Q4: Will new delivery methods influence the market?
A4: Yes, innovations like port delivery systems could reduce injection frequency and alter treatment costs.
Q5: How does biosimilar competition typically affect drug prices?
A5: It usually results in a 20–30% decrease in price, depending on market adoption and regulatory approvals.
References
- MarketWatch. (2023). Global retinal drug market statistics.
- IQVIA. (2022). US ophthalmic pharmaceuticals report.
- FDA. (2022). Biosimilar approvals in ophthalmology.
- EvaluatePharma. (2022). Top ophthalmic drugs by revenue.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for retinal drugs.
[1] APA Citations would follow in the final.
